Fig. 1: Predicted probability of anti-spike IgG positivity by time from first vaccination for comparisons of age by vaccine type and prior infection status.
The data are from 40,131 participants without prior infection and 5,834 participants with prior infection. a, No prior infection and received one dose of ChAdOx1. b, No prior infection and received one dose of BNT162b2. c, No prior infection and received two doses of BNT162b2. d, With prior infection and received one dose of ChAdOx1. e, With prior infection and received one dose of BNT162b2. f, For those who received two doses of BNT162b2 without prior infection, the chart shows the percentage of participants having had two vaccine doses by each time point (grey, had two doses; blue, had only one dose). Different x axis scales reflect different durations of follow-up post-vaccination in the different cohorts. Line colour indicates antibody response predicted for ages 20, 40, 60 and 80 years (see Extended Data Fig. 2 for the full model across all ages and comparisons of vaccine type by age). The 95% CIs are calculated by prediction ± 1.96 × standard error of prediction.
